BioNexus announced continued progress in commercializing the VitaGuard platform in Southeast Asia following a working visit to Tongshu Gene sites in China led by Dr. Muthu Meyyappan. This development demonstrates tangible market relevance for BioNexus' direct path into precision oncology through its global portfolio of liquid biopsy solutions.